Ajay Major, MD, MBA
@majorajay.bsky.social
Lymphoma/CLL faculty at the University of Colorado School of Medicine. Patient-reported outcomes methodologist & #lymsm quality of life investigator. #medsky
Pinned
Check out all of this year's #MajorPROsASH, the top 20 best patient-reported outcomes & quality of life abstracts from #ASH24. 🧵 #ASHEducation #ASHKudos cc @ash-hematology.bsky.social
Many thanks to @cucancercenter.bsky.social for highlighting our paper about colorectal cancer in childhood cancer survivors: 50% were diagnosed before age 40, with much work to do improving screening rates.
Read manuscript here: academic.oup.com/jnci/advance...
news.cuanschutz.edu/cancer-cente...
Read manuscript here: academic.oup.com/jnci/advance...
news.cuanschutz.edu/cancer-cente...
Why Childhood Cancer Survivors Are at Higher Risk of Colorectal Cancer — and What Their Doctors Can Do About It
Ajay Major's research found childhood cancer survivors got subsequent colorectal cancer at younger ages and had high colorectal cancer mortality rates.
news.cuanschutz.edu
November 24, 2025 at 10:06 PM
Many thanks to @cucancercenter.bsky.social for highlighting our paper about colorectal cancer in childhood cancer survivors: 50% were diagnosed before age 40, with much work to do improving screening rates.
Read manuscript here: academic.oup.com/jnci/advance...
news.cuanschutz.edu/cancer-cente...
Read manuscript here: academic.oup.com/jnci/advance...
news.cuanschutz.edu/cancer-cente...
Double-dose axi-cel 2L high-risk LBCL #ASH25
- 15 pts, 69% refractory, 4 couldn't get 2nd dose
- no DLTs w/i 28 days
- ORR 91% (CR 73%), 6-mo PFS 79%, 100% OS
- 3 G1 CRS/ICANS after 2nd dose
Correlative data: less CAR exhaustion & better cytotox after 2nd dose. #lymsm #tcellrx
- 15 pts, 69% refractory, 4 couldn't get 2nd dose
- no DLTs w/i 28 days
- ORR 91% (CR 73%), 6-mo PFS 79%, 100% OS
- 3 G1 CRS/ICANS after 2nd dose
Correlative data: less CAR exhaustion & better cytotox after 2nd dose. #lymsm #tcellrx
November 24, 2025 at 6:32 PM
Pirto vs BR 1L CLL LBA #ASH25
- 282 pts (TP53mut not allowed)
- 2-yr PFS 93% with pirto, 71% with BR
- superior OS with pirto despite 53% crossover
- PFS benefit seen in IGHV unmut
- G5 AEs: 1 pirto, 4 BR; more d/c with BR
Not a useful comparator arm, but very few pirto AEs. #lymsm
- 282 pts (TP53mut not allowed)
- 2-yr PFS 93% with pirto, 71% with BR
- superior OS with pirto despite 53% crossover
- PFS benefit seen in IGHV unmut
- G5 AEs: 1 pirto, 4 BR; more d/c with BR
Not a useful comparator arm, but very few pirto AEs. #lymsm
November 24, 2025 at 5:40 PM
The #ASH25 late-breaking abstracts are out! Will review the pirto vs BR abstract shortly. #lymsm cc @ash.hematology.org submit.hematology.org/program/sess...
November 24, 2025 at 5:35 PM
The #ASH25 late-breaking abstracts are out! Will review the pirto vs BR abstract shortly. #lymsm cc @ash.hematology.org submit.hematology.org/program/sess...
Reposted by Ajay Major, MD, MBA
Immunotherapies stand out as a defining theme of #ASH25. @majorajay.bsky.social previews three hot Education Program sessions.
🔗Innovation to Integration: The Next Phase of Immunotherapies in Myeloma, Leukemia, and Lymphoma: ow.ly/Y4lo50XvNLB #lymsm #leusm #mmsm #HemeSky #MedSky
5/6
🔗Innovation to Integration: The Next Phase of Immunotherapies in Myeloma, Leukemia, and Lymphoma: ow.ly/Y4lo50XvNLB #lymsm #leusm #mmsm #HemeSky #MedSky
5/6
November 22, 2025 at 12:45 PM
Immunotherapies stand out as a defining theme of #ASH25. @majorajay.bsky.social previews three hot Education Program sessions.
🔗Innovation to Integration: The Next Phase of Immunotherapies in Myeloma, Leukemia, and Lymphoma: ow.ly/Y4lo50XvNLB #lymsm #leusm #mmsm #HemeSky #MedSky
5/6
🔗Innovation to Integration: The Next Phase of Immunotherapies in Myeloma, Leukemia, and Lymphoma: ow.ly/Y4lo50XvNLB #lymsm #leusm #mmsm #HemeSky #MedSky
5/6
Excited to work with this phenomenal team of hematologists on ASH News Daily for #ASH25 this year!
Be sure to check out our first set of articles here: ashpublications.org/ashnewsdaily...
#ASHNewsDaily @ash.hematology.org
Be sure to check out our first set of articles here: ashpublications.org/ashnewsdaily...
#ASHNewsDaily @ash.hematology.org
November 18, 2025 at 8:04 PM
Excited to work with this phenomenal team of hematologists on ASH News Daily for #ASH25 this year!
Be sure to check out our first set of articles here: ashpublications.org/ashnewsdaily...
#ASHNewsDaily @ash.hematology.org
Be sure to check out our first set of articles here: ashpublications.org/ashnewsdaily...
#ASHNewsDaily @ash.hematology.org
Neuropathy in ASPEN trial (ibr v zanu in WM)
- 49/201 w/ baseline PN (clinician assessed; no PN PRO included); 10 anti-MAG
- 71% PN resolution (median 10 mos)
- much better global QOL improvement if PN resolved
Need PRO PN studies in WM. #lymsm #ASH25
www.sciencedirect.com/science/arti...
- 49/201 w/ baseline PN (clinician assessed; no PN PRO included); 10 anti-MAG
- 71% PN resolution (median 10 mos)
- much better global QOL improvement if PN resolved
Need PRO PN studies in WM. #lymsm #ASH25
www.sciencedirect.com/science/arti...
November 17, 2025 at 9:15 PM
Neuropathy in ASPEN trial (ibr v zanu in WM)
- 49/201 w/ baseline PN (clinician assessed; no PN PRO included); 10 anti-MAG
- 71% PN resolution (median 10 mos)
- much better global QOL improvement if PN resolved
Need PRO PN studies in WM. #lymsm #ASH25
www.sciencedirect.com/science/arti...
- 49/201 w/ baseline PN (clinician assessed; no PN PRO included); 10 anti-MAG
- 71% PN resolution (median 10 mos)
- much better global QOL improvement if PN resolved
Need PRO PN studies in WM. #lymsm #ASH25
www.sciencedirect.com/science/arti...
RW outcomes CD19 CAR Burkitt
- 31 pts, 3 prior LOT, most axi-cel
- 65% G3+ CRS, 19% G3+ ICANS
- 16% D+28 mortality (!!!)
- 6-mo CR 19%, mPFS 2.3 mos, mOS 6 mos
- 3 pts who got post-CAR allo all relapsed
Dismal outcomes & unmet need (BsAb? alloCAR?) #lymsm #ASH25 ashpublications.org/blood/articl...
- 31 pts, 3 prior LOT, most axi-cel
- 65% G3+ CRS, 19% G3+ ICANS
- 16% D+28 mortality (!!!)
- 6-mo CR 19%, mPFS 2.3 mos, mOS 6 mos
- 3 pts who got post-CAR allo all relapsed
Dismal outcomes & unmet need (BsAb? alloCAR?) #lymsm #ASH25 ashpublications.org/blood/articl...
November 17, 2025 at 8:21 PM
RW outcomes CD19 CAR Burkitt
- 31 pts, 3 prior LOT, most axi-cel
- 65% G3+ CRS, 19% G3+ ICANS
- 16% D+28 mortality (!!!)
- 6-mo CR 19%, mPFS 2.3 mos, mOS 6 mos
- 3 pts who got post-CAR allo all relapsed
Dismal outcomes & unmet need (BsAb? alloCAR?) #lymsm #ASH25 ashpublications.org/blood/articl...
- 31 pts, 3 prior LOT, most axi-cel
- 65% G3+ CRS, 19% G3+ ICANS
- 16% D+28 mortality (!!!)
- 6-mo CR 19%, mPFS 2.3 mos, mOS 6 mos
- 3 pts who got post-CAR allo all relapsed
Dismal outcomes & unmet need (BsAb? alloCAR?) #lymsm #ASH25 ashpublications.org/blood/articl...
I'm writing for #ASHNewsDaily this year! Check out my article previewing #ASH25 Education Program talks about immunotherapies invading earlier lines of therapy, including interviews with Drs. Doris Hansen, Nicolas Boissel & Sarah Rutherford. cc @ash.hematology.org
ashpublications.org/ashnewsdaily...
ashpublications.org/ashnewsdaily...
November 17, 2025 at 4:28 PM
I'm writing for #ASHNewsDaily this year! Check out my article previewing #ASH25 Education Program talks about immunotherapies invading earlier lines of therapy, including interviews with Drs. Doris Hansen, Nicolas Boissel & Sarah Rutherford. cc @ash.hematology.org
ashpublications.org/ashnewsdaily...
ashpublications.org/ashnewsdaily...
CRS/ICANS onset after liso-cel
- 702 trial pts: 98%/88% before D+15
- 877 RW pts: 97%/95% before D+15
- no G3+ CRS/ICANS after D+15 in trial pts, only 2 G3-4 events in RW population
This led to change in REMS to only 2 weeks of monitoring after CAR. #oncsky
www.sciencedirect.com/science/arti...
- 702 trial pts: 98%/88% before D+15
- 877 RW pts: 97%/95% before D+15
- no G3+ CRS/ICANS after D+15 in trial pts, only 2 G3-4 events in RW population
This led to change in REMS to only 2 weeks of monitoring after CAR. #oncsky
www.sciencedirect.com/science/arti...
CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting
Improved understanding of the timing of cytokine release syndrome (CRS) and immune effector cell–mediated neurotoxicity syndrome (ICANS)/neurological …
www.sciencedirect.com
November 17, 2025 at 4:09 PM
CRS/ICANS onset after liso-cel
- 702 trial pts: 98%/88% before D+15
- 877 RW pts: 97%/95% before D+15
- no G3+ CRS/ICANS after D+15 in trial pts, only 2 G3-4 events in RW population
This led to change in REMS to only 2 weeks of monitoring after CAR. #oncsky
www.sciencedirect.com/science/arti...
- 702 trial pts: 98%/88% before D+15
- 877 RW pts: 97%/95% before D+15
- no G3+ CRS/ICANS after D+15 in trial pts, only 2 G3-4 events in RW population
This led to change in REMS to only 2 weeks of monitoring after CAR. #oncsky
www.sciencedirect.com/science/arti...
This is what happens when all the junior @cuhematology.bsky.social lymphoma faculty have clinic on Fridays. #lymsm 😂😂
November 14, 2025 at 6:59 PM
This is what happens when all the junior @cuhematology.bsky.social lymphoma faculty have clinic on Fridays. #lymsm 😂😂
Announcing the MAGIC-ONC guidelines for the placement and management of vascular access devices in patients with cancer, including specific recommendations for both hematologic and solid tumor malignancies. #MAGICOnc #oncsky #medsky
www.acpjournals.org/doi/epdf/10.... cc @cuanschutz.bsky.social
www.acpjournals.org/doi/epdf/10.... cc @cuanschutz.bsky.social
November 4, 2025 at 10:47 PM
Announcing the MAGIC-ONC guidelines for the placement and management of vascular access devices in patients with cancer, including specific recommendations for both hematologic and solid tumor malignancies. #MAGICOnc #oncsky #medsky
www.acpjournals.org/doi/epdf/10.... cc @cuanschutz.bsky.social
www.acpjournals.org/doi/epdf/10.... cc @cuanschutz.bsky.social
Reposted by Ajay Major, MD, MBA
Finally out - our real world study of 740 patients with large B-cell lymphoma receiving polatuzumab vedotin shows higher response rates and PFS for patients with non-GCB LBCL than those with GCB disease, by Hans algorithm.
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
November 4, 2025 at 9:53 AM
Finally out - our real world study of 740 patients with large B-cell lymphoma receiving polatuzumab vedotin shows higher response rates and PFS for patients with non-GCB LBCL than those with GCB disease, by Hans algorithm.
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
Reposted by Ajay Major, MD, MBA
An important step forward in improving vascular access safety for patients with cancer, introducing the MAGIC-ONC guidelines!
www.acpjournals.org/doi/epdf/10....
www.acpjournals.org/doi/epdf/10....
November 4, 2025 at 5:36 AM
An important step forward in improving vascular access safety for patients with cancer, introducing the MAGIC-ONC guidelines!
www.acpjournals.org/doi/epdf/10....
www.acpjournals.org/doi/epdf/10....
Reposted by Ajay Major, MD, MBA
Woah! @majorajay.bsky.social thinking through just about every hematology/oncology vascular access question possible (1422 scenarios, to be exact) to guide access choice. #medsky #oncsky #nursesky
Just a few examples below:
Just a few examples below:
November 4, 2025 at 4:28 AM
Woah! @majorajay.bsky.social thinking through just about every hematology/oncology vascular access question possible (1422 scenarios, to be exact) to guide access choice. #medsky #oncsky #nursesky
Just a few examples below:
Just a few examples below:
Late night publication (finally!) of our MAGIC-ONC appropriateness guidelines for vascular access in patients with cancer, now in @annalsofim.bsky.social. More to come tomorrow! #medsky #oncsky www.acpjournals.org/doi/full/10....
November 4, 2025 at 2:16 AM
Late night publication (finally!) of our MAGIC-ONC appropriateness guidelines for vascular access in patients with cancer, now in @annalsofim.bsky.social. More to come tomorrow! #medsky #oncsky www.acpjournals.org/doi/full/10....
Dr. Valerie Crabtree @stjude.bsky.social presented the findings of our qualitative study of patient and care partner perspectives in NLPHL at @worldsiop.bsky.social #SIOPCongress. Read our study here: pubmed.ncbi.nlm.nih.gov/40059593/ #lymsm cc @cucancercenter.bsky.social @cuanschutz.bsky.social
October 30, 2025 at 8:26 PM
Dr. Valerie Crabtree @stjude.bsky.social presented the findings of our qualitative study of patient and care partner perspectives in NLPHL at @worldsiop.bsky.social #SIOPCongress. Read our study here: pubmed.ncbi.nlm.nih.gov/40059593/ #lymsm cc @cucancercenter.bsky.social @cuanschutz.bsky.social
This morning's meeting of our monthly @accordsresearch.bsky.social imPROve Patient-Reported Outcomes Working Group. Phenomenal group of @cuanschutz.bsky.social @cucancercenter.bsky.social investigators working on new quality of life studies. #HRQoL medschool.cuanschutz.edu/accords/rese...
October 28, 2025 at 3:40 PM
This morning's meeting of our monthly @accordsresearch.bsky.social imPROve Patient-Reported Outcomes Working Group. Phenomenal group of @cuanschutz.bsky.social @cucancercenter.bsky.social investigators working on new quality of life studies. #HRQoL medschool.cuanschutz.edu/accords/rese...
RW pola outcomes by Hans COO @eddiecliff.bsky.social
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
October 27, 2025 at 4:30 PM
RW pola outcomes by Hans COO @eddiecliff.bsky.social
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
The first report of quality of life in patients with NLPHL from our ongoing NLPHLPRO multicenter trial (NCT06098430), presented by Dr. Jones at #ISCAYAHL.
Long-term survivors (most who received chemo) have low symptom burden and high global QOL & functioning. #lymsm cc @cuhematology.bsky.social
Long-term survivors (most who received chemo) have low symptom burden and high global QOL & functioning. #lymsm cc @cuhematology.bsky.social
October 23, 2025 at 8:05 PM
The first report of quality of life in patients with NLPHL from our ongoing NLPHLPRO multicenter trial (NCT06098430), presented by Dr. Jones at #ISCAYAHL.
Long-term survivors (most who received chemo) have low symptom burden and high global QOL & functioning. #lymsm cc @cuhematology.bsky.social
Long-term survivors (most who received chemo) have low symptom burden and high global QOL & functioning. #lymsm cc @cuhematology.bsky.social
Interested in adding PROs to your study, or developing a quality of life project?
Come to our imPROve Working Group @accordsresearch.bsky.social to get feedback from PRO researchers across @childrenscolo.bsky.social @cuanschutz.bsky.social. #oncsky
medschool.cuanschutz.edu/accords/rese...
Come to our imPROve Working Group @accordsresearch.bsky.social to get feedback from PRO researchers across @childrenscolo.bsky.social @cuanschutz.bsky.social. #oncsky
medschool.cuanschutz.edu/accords/rese...
October 20, 2025 at 5:06 PM
Interested in adding PROs to your study, or developing a quality of life project?
Come to our imPROve Working Group @accordsresearch.bsky.social to get feedback from PRO researchers across @childrenscolo.bsky.social @cuanschutz.bsky.social. #oncsky
medschool.cuanschutz.edu/accords/rese...
Come to our imPROve Working Group @accordsresearch.bsky.social to get feedback from PRO researchers across @childrenscolo.bsky.social @cuanschutz.bsky.social. #oncsky
medschool.cuanschutz.edu/accords/rese...
CAR-T in PCNSL #lymsm
- 67 pts, 25% CSF+, 12% eye+
- 57% axicel, 30% tisacel
- 58% CR, 1-yr PFS 50%, OS 66%
- 2-yr RFS better if CR/PR at CAR infusion: 56% vs 28%
- 27% G3+ ICANS!
Almost all got bridging; would love to know which agents.
academic.oup.com/neuro-oncolo...
- 67 pts, 25% CSF+, 12% eye+
- 57% axicel, 30% tisacel
- 58% CR, 1-yr PFS 50%, OS 66%
- 2-yr RFS better if CR/PR at CAR infusion: 56% vs 28%
- 27% G3+ ICANS!
Almost all got bridging; would love to know which agents.
academic.oup.com/neuro-oncolo...
P14.07.B CAR T-CELL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS: A MULTICENTER RETROSPECTIVE STUDY FROM THE LOC NETWORK
AbstractBACKGROUND. The use of CAR T-cell therapy has been delayed in primary central nervous system lymphomas (PCNSL) due to the fear of unacceptable neur
academic.oup.com
October 20, 2025 at 2:01 PM
CAR-T in PCNSL #lymsm
- 67 pts, 25% CSF+, 12% eye+
- 57% axicel, 30% tisacel
- 58% CR, 1-yr PFS 50%, OS 66%
- 2-yr RFS better if CR/PR at CAR infusion: 56% vs 28%
- 27% G3+ ICANS!
Almost all got bridging; would love to know which agents.
academic.oup.com/neuro-oncolo...
- 67 pts, 25% CSF+, 12% eye+
- 57% axicel, 30% tisacel
- 58% CR, 1-yr PFS 50%, OS 66%
- 2-yr RFS better if CR/PR at CAR infusion: 56% vs 28%
- 27% G3+ ICANS!
Almost all got bridging; would love to know which agents.
academic.oup.com/neuro-oncolo...
Patient- vs clinician-reported AEs from POLARIX @bloodjournals.hematology.org:
- symptom incidence & severity much higher measured by PROs
- sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm)
We must measure PROs in #lymsm trials!
ashpublications.org/blood/articl...
- symptom incidence & severity much higher measured by PROs
- sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm)
We must measure PROs in #lymsm trials!
ashpublications.org/blood/articl...
October 14, 2025 at 7:58 PM
Patient- vs clinician-reported AEs from POLARIX @bloodjournals.hematology.org:
- symptom incidence & severity much higher measured by PROs
- sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm)
We must measure PROs in #lymsm trials!
ashpublications.org/blood/articl...
- symptom incidence & severity much higher measured by PROs
- sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm)
We must measure PROs in #lymsm trials!
ashpublications.org/blood/articl...